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Introduction
 Increasing evidence suggests a crucial role for the microcirculation 
in the causation of hypertension and cardiovascular disease [1]. Im-
paired tissue perfusion secondary to microcirculatory abnormalities 
is also implicated in the pathogenesis of obesity, diabetes mellitus and 
insulin resistance [2]. A reduction in the density (rarefaction) of capil-
laries and arterioles is a consistent finding among the many functional 
and structural microcirculatory abnormalities that occur in human 
hypertension [3]. We have previously shown that much of the capil-
lary rarefaction in hypertension is due to the structural (i.e., Anatom-
ic) absence of capillaries [4]. We have also shown significant capillary 
rarefaction in patients with borderline intermittent hypertension as 
well as in normotensive offspring of hypertensive parents suggesting 
that capillary rarefaction may be a primary abnormality that pre-
cedes the onset of hypertension [5-7]. Furthermore we have recently 
demonstrated that alterations in structural capillary density in early 
pregnancy can accurately and independently predict preeclampsia 
[8,9]. Therefore the improvement of microvascular abnormalities rep-
resents pertinent therapeutic targets [10]. However few observational 
and open label studies have shown non-consistent results about the 
reversal of micro vascular rarefaction with antihypertensive treat-
ments [10-13].
 The aim of the CAMIRA trial was to assess in a randomized, 
double blind, placebo controlled two-arm parallel group clini-
cal trial. The effects of treatment of hypertension with the An-
giotensin Receptor Blocker (ARB) candesartan versus the di-
hydropyridine Calcium Channel Blocker (CCB) amlodipine 
on micro vascular rarefaction and other indices of vascular function 
in individuals with mild-to-moderate essential hypertension.
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Abstract
Background: A reduction in the density of capillaries (rarefaction) 
is known to occur in many tissues in patients with essential hyper-
tension and play a role in increasing Blood Pressure (BP). The aim 
of this trial was to assess in a randomized, double blind, design the 
effects of treatment of hypertension with candesartan versus am-
lodipine on microvascular rarefaction and other indices of vascular 
function.
Methods: We recruited twenty-two individuals with mild-to-mod-
erate hypertension. After a 2-week placebo run-in period, patients 
who remained hypertensive (≥140/90 mmHg) were randomized to 
8-weeks treatment with Candesartan tablets 8mg daily (with forced 
titration to 16mg) or Amlodipine tablets 5mg daily (with forced titra-
tion to 10mg). The capillary microcirculation was studied using Cap-
iScope system CAM1. Pulse wave velocity, central BP and aortic 
Augmentation Index were also measured.
Results: We observed significant reductions in brachial BP, and 
central BP after 4 and 8 weeks treatment with either candesartan or 
amlodipine but there was no significant effect on basal (functional) 
or maximal (structural) capillary densities, or pulse wave velocity.
Conclusion: Eight weeks treatment of hypertension with either 
amlodipine or candesartan significantly reduced brachial and cen-
tral BP but was not sufficient to induce a regression in functional or 
structural microvascular abnormalities.
Keywords: Amlodipine; Candesartan; Capillary density; Capillary 
rarefaction; Hypertension; Microcirculation
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Methodology
Participants
 The CAMIRA trial (Eudra CT number: 2008-005432-32, IS-
RCTN 62554526) was a single center, randomized, double blind, 
placebo-controlled, parallel-group  study performed at St. George’s 
Healthcare NHS Trust hospital (London, UK). The London-Surrey 
Borders Research Ethics Committee approved the study (number 08/
H0806/72). Written informed consent was obtained from all partic-
ipants. We recruited Caucasian individuals with mild-to-moderate 
uncomplicated essential hypertension (sitting systolic BP ≥140-<180 
mmHg and/or sitting diastolic BP ≥ 90-<110 mmHg) who have never 
been previously treated for their high BP or have been off their anti-
hypertensive medications for at least 8 weeks. Patients were exclud-
ed from the study if they had diabetes mellitus (fasting plasma glu-
cose ≥7.0mmol/L, random plasma glucose ≥11.1mmol/L or HbA1c 
>6.5%) secondary hypertension (excluded hyperaldosteronism, renal 
artery stenosis, pheochromocytoma by measuring plasma renin, plas-
ma aldosterone, 24 hour urinary metanephrines, magnetic resonance 
imaging of renal arteries), chronic kidney or liver disease (normal 
renal & liver function tests), ischemic heart disease (normal ECG), 
heart failure (normal echocardiogram), skin diseases, or cold hands 
(measuring skin temperature).
 After a 2-weeks single-blind placebo run-in period, patients who 
remained hypertensive (systolic BP 140–180 mmHg and/or diastolic 
BP 90-110 mmHg) were randomized to 8-weeks treatment with either 
candesartan 8mg orally once daily (with forced titration to 16mg once 
daily after 2 weeks) or amlodipine 5mg orally once daily (with forced 
titration to 10mg once daily after 2 weeks). Total study duration was 
10 weeks.
Blood pressure measurement
 At each visit, subjects were seated with their backs supported for at 
least 10 minutes in a temperature-controlled room. All measurements 
were taken throughout the study from the same arm. Three sitting 
and 2 standing BP measurements were obtained at 2-minute intervals 
using appropriate cuff size using the Omron HEM705CP (Hutchings 
Health Care Ltd., Sussex, UK).
Intravital capillary microscopy studies (Capillaroscopy)
 Previously validated methods 4-6, were used to assess capillary 
density in the skin of the dorsum of the fingers [14]. The studies were 
performed in a temperature-controlled laboratory (21°-24° C) after the 
study subjects had at least 20-minute rest for acclimatization. Subjects 
were seated with the left arm and hand supported at heart level. Mi-
croscopic images were obtained using the CapiScope system CAM1 
and the number of capillaries was counted on-line using computer 
software (KK Technology, Exeter, UK). Basal Capillary Density (BCD) 
represents the number of capillaries that are “open” or “functioning” at 
the time of measurement and was calculated as the mean of 4 micro-
scopic fields.
Maximization of capillaries
 A miniature BP cuff was wrapped around the base of the finger 
and was then inflated to 60mmHg and further images were recorded 
using one of the above four fields chosen at random. Venous conges-
tion was maintained for 2 minutes [14]. Skin and room temperatures 
were monitored at each visit. Capillaroscopy measurements were 
performed at the end of the placebo-run in visit, after 4-weeks and 
8-weeks of active drug treatment.
Carotid-Femoral Pulse Wave Velocity (PWV) measurements
 PWV was measured non-invasively using the COMPLIOR device 
as previously described [15]. Two different pressure wave signals were 
recorded simultaneously using pressure sensitive transducers placed 
on the skin at two sites, the right common carotid artery and the right 
femoral artery. All calculations over 10-12 cardiac cycles were auto-
mated.
Aortic Augmentation Index (AI) & central Aortic Pressure 
(cSBP)
 AI and cSBP were measured using the Omron HEM-9000AI de-
vice (Omron Healthcare, Kyoto, Japan) [16]. Radial artery tonometry 
was performed on the left arm of each participant, and BP was mea-
sured. All vascular measurements were performed by a single experi-
enced operator (R.R.) in a quiet temperature-controlled laboratory.
Laboratory tests
 Blood and urine samples were obtained at entry to the study, end 
of placebo run-in period and after 4 weeks and 8 weeks of active drug 
treatment. Variables measured were serum electrolytes, urea, creati-
nine, uric acid, glucose, total cholesterol, triglycerides and full blood 
count. 24 hour urinary excretion of sodium, potassium and creatinine 
were measured as well.
Statistical analysis
 The primary outcome variable was the change in maximal (struc-
tural) skin capillary density during venous congestion after 8 weeks 
of active treatment. All other variables recorded were prospectively 
defined as secondary outcome criteria. The mean, Standard Deviation 
(SD) and range are reported for all continuous variables, which were 
normally distributed. For maximal capillary density during venous 
congestion, an analysis of covariance was performed adjusted on bas-
al capillary density and age. Pair wise comparisons between groups 
and within groups were performed using this analysis of covariance 
model, without adjustment for multiple comparisons in this prelimi-
nary approach. All other parameters were analyzed similarly. Student’s 
paired and unpaired t- tests were used to evaluate differences between 
and among groups. For the other criteria, difference between groups 
was assessed with a two tailed Student’s T test for independent sam-
ples or with nonparametric test for non normal distribution. A type 
error of 5% was set for all test procedures.
 Statistical significance was declared when the p-value was <0.05. 
All statistical analysis was carried out using the IBM SPSS 22, USA.
Results
 A total of 155 Caucasian subjects were invited to participate in 
the study and subsequently 114 subjects were screened for eligibility. 
Of these, 42 individuals did not meet the inclusion criteria (mainly 
because of normalization of their BP on the follow-up visit), 38 sub-
jects withdrew consent, 8 were found to be receiving antihypertensive 
medications from their general practitioner and 4 had abnormal labo-
ratory results. Eventually 22 subjects were recruited into the study but 
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1 subject withdrew consent during the run-in period. Table 1 shows 
the baseline characteristics of the recruited subjects. The average age 
of the subjects was 42.4 years (range 26-59 years) and the average BMI 
was 29.0 (range 20.0-43.2). At entry to the study mean±SD sitting 
and standing BP were 147/97±14/8mmHg and 147/96±16/8mmHg 
respectively.
 At the end of the 2 weeks single blind placebo run-in period mean 
sitting BP was144/94±14/9mmHg (p=0.07 and p=0.057 respectively 
compared to baseline levels). In six subjects the BP dropped signifi-
cantly on placebo, so much so they did not meet the inclusion criteria 
and were therefore excluded form the randomized phase. There were 
no significant changes in other clinical or laboratory parameters. Ta-
ble 2 shows the baseline characteristics of the randomized subjects. In 
total 9 subjects were randomized to candesartan and 6 subjects were 
randomized to amlodipine. Table 3 shows the longitudinal chang-
es in BMI, sitting and standing systolic and diastolic BP, pulse rate, 
central systolic BP, PWV, basal and maximal capillary densities and 
aortic augmentation from baseline.
Blood pressure changes
 In paired comparisons of sitting systolic BP, there was a signifi-
cant decrease from the end of the placebo run-in period to 4 weeks 
active treatment (mean change-19.0 mmHg; 95% CI -11.1 to -26.9, 
p<0.0001) and to 8 weeks active treatment (mean change -26.3 
mmHg; 95% CI -17.5 to -35.0, p<0.0001) (Table 3). Similarly there was 
a significant decrease in sitting diastolic BP at 4 weeks active treatment 
(mean change-13.8 mmHg; 95% CI -9.8 to -17.7, p<0.0001) and to 8 
weeks active treatment (mean change -16.1 mmHg; 95% CI -13.1 to 
-19.0, p<0.0001. For standing systolic BP, there was also a significant 
decrease at 4 weeks active treatment (mean change -21.9 mmHg; 95% 
CI -11.1 to -32.7, p=0.001) and to 8 weeks active treatment (mean 
change -26.5 mmHg; 95% CI -15.8 to -37.3, p<0.0001). Standing di-
astolic BP decreased significantly after 4 weeks of active treatment 
(mean change -11.8 mmHg; 95% CI -6.4 to -17.3, p<0.0001) and to 
8 weeks active treatment (mean change-16.1 mmHg; 95% CI -11.4 to 
-20.8, p<0.0001). There were no significant differences between the 
responses to amlodipine versus candesartan in all BP parameters.
Variable All (N=21)
Age, years 42.4(9.4)
Sex, M/F 14/7
Weight, Kg 88.0(16.8)
BMI, kg/m2 29.0(5.2)
Waist circumference, cm 101.4(13.0)
Hip circumference, cm 107.3(11.9)
Blood Pressure, mmHg
Sitting 147/97(14/8)
Standing 147/96(16/8)
Mean Blood Pressure, mmHg
Sitting 113.7(8.9)
Standing 110.3(10.0)
Heart rate, beats/m 72.1(10.1)
Smoking history
Yes 4(19.0%)
No 13(61.9%)
Ex-smoker 4(19.0%)
Family History
Ischaemic Heart Disease 10(47.6%)
Hypertension 13(61.9%)
Stroke 5(23.8%)
Laboratory results
Haemoglobin, gm/dL 14.7(1.4)
Serum sodium, mmol/L 139.6(2.0)
Serum potassium, mmol/L 4.3(0.3)
Serum glucose, mmol/L 4.8(0.56)
Total cholesterol, mmol/L 5.1(1.0)
LDL-cholesterol, mmol/L 2.9(0.8)
HDL-cholesterol, mmol/L 1.4(0.3)
24h Urinary sodium, mmol 115(72)
24h Urinary potassium, mmol 53(18)
Variable All  (N=15) Amlodipine Group (N=6)
Candesartan 
Group (N=9)
Age, years 44.6(8.1) 40.8(7.6) 47.1(7.8)
Male, n (%) 5(33.3) 2(33.3) 3(33.3)
Weight, Kg 90.9(14.4) 88.5(7.9) 92.5(17.8)
BMI, kg/m2 29.9(4.8) 29.2(2.7) 30.3(5.9)
Waist circumfer-
ence, cm 101.5(12.3) 95.3(9.9) 105.7(12.4)
Hip circumfer-
ence, cm 110.7(7.7) 109.0(1.5) 111.8(9.9)
Heart rate, b/m 72.6(8.3) 66.2(6.0) 76.9(6.8)
Smoking n (%)
Yes 2(13.3) 0(0.0) 2(22.2)
No 11(73.3) 5(83.3) 6(66.7)
Ex-smoker 2(13.3) 1(16.7) 1(11.1)
Family History
Ischaemic heart 
disease 7(46.7) 3(50.0) 4(44.4)
Hypertension 10(66.7) 6(100) 4(44.4)
Stroke 4(26.7) 2(33.3) 2(22.2)
Blood pressure, mmHg
Sitting 149/96(14/7) 144/99(18/7) 150/95(12/8)
Standing 148/98(15/7) 143/99(18/8) 152/96(11/7)
Central blood 
pressure, 144/92(14/10) 139/94(16/14) 148/91(13/6)
Pulse wave 
velocity, m/sec 9.7(1.2) 9.5(1.3) 9.9(1.2)
Augmentation 
Index 75.1(10.4) 74.0(5.9) 75.8(12.6)
Basal Capillary 
Density  (per 
field)
49.6(6.2) 51.7(5.5) 48.1(6.5)
Maximal Capillary 
density (per field)
53.2(6.7) 53.8(7.8) 52.7(6.2)
Table 1: Baseline characteristics of recruited subjects at the start of the pla-
cebo run-in period.
Table 2: Baseline characteristics of randomized subjects.
Results are presented as Mean(SD)
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Central systolic blood pressure and aortic augmentation 
changes
 cSBP decreased significantly after 4 weeks of treatment (mean 
change -18.4 mmHg; 95% CI -8.0 to -28.8, p=0.002) and after 8 weeks 
(mean change -22.6 mmHg; 95% CI -13.6 to -31.6, p<0.0001). AI also 
decreased significantly after 4 weeks of treatment (mean change -7.6 
mmHg; 95% CI -2.2 to -13.0, p=0.010) and after 8 weeks (mean change 
-9.2 mmHg; 95% CI -4.7 to -13.6, p=0.001). There were no significant 
differences between the responses to amlodipine versus candesartan.
Pulse wave velocity
 The changes in PWV were not significant at any point in the study 
(Table 3). We could not rule out the possibility that we have not seen 
significant differences because of the small number of subjects.
Capillary density changes
 There were no significant changes in basal (i.e., before venous 
congestion) capillary density after 4 weeks (mean change -0.4 cap/
field; 95% CI -3.5 to 2.6, p=0.76) or after 8 weeks of active treatment 
(mean change 1.2 cap/field; 95% CI -2.3 to 4.7, p=0.48). Similarly, 
there were no significant changes in maximal (i.e., with venous con-
gestion) capillary density after 4 weeks (mean change 1.5 cap/field; 
95% CI -2.1 to 5.2, p=0.38) or after 8 weeks of active treatment (mean 
change 1.8 cap/field; 95% CI -1.1 to 1.8, p=0.20).
Discussion
 This is the first randomized, double blind, placebo controlled, par-
allel-group study aimed at comparing the effects of treatment of hy-
pertension with a CCB versus an ARB on skin capillary density in hy-
pertensive patients using well-validated techniques. The study showed 
that after 4 weeks and 8 weeks treatment with either candesartan or 
amlodipine, there were significant reductions in both systolic and di-
astolic brachial BP and central systolic BP but there was no significant 
affection basal (functional) or maximal (structural) capillary densi-
ties. The study also showed that both candesartan and amlodipine 
Variable
All Candesartan Amlodipine Between Groups t test 
p-value t-test Overall p-valueMean (SE) change Mean (SE) change Mean (SE) change
Sitting Systolic BP (mmHg)
4 weeks treatment -19.0(3.7) -19.4(5.6) -18.5(4.8) 0.25 <0.0001
8 weeks treatment -26.3(4.0) -29.4(5.6) -21.8(5.4) 0.94 <0.0001
Sitting Diastolic BP (mmHg)
4 weeks treatment -13.8(1.8) -11.8(2.5) -16.5(2.5) 0.93 <0.0001
8 weeks treatment -16.1(1.3) -15.9(1.8) -16.4(2.3) 0.49 <0.0001
Sitting Mean BP (mmHg)
4 weeks treatment -15.0(2.4) -14.5(3.3) -15.8(3.8) 0.8 <0.0001
8 weeks treatment -18.7(2.4) -20.6(2.7) -16.1(4.5) 0.39 <0.0001
Standing Systolic BP (mmHg)
4 weeks treatment -21.9(5.0) -24.8(5.3) -17.4(10.2) 0.63 <0.0001
8 weeks treatment -26.5(4.8) -30.1(4.0) -20.3(11.6) 0.88 <0.0001
Standing Diastolic BP (mmHg)
4 weeks treatment -11.8(2.5) -11.0(3.2) -13.2(4.4) 0.99 <0.0001
8 weeks treatment -16.1(2.1) -16.4(1.8) -15.5(5.4) 0.24 <0.0001
Basal Capillary Density (capillaries per field)
4 weeks treatment -0.4(1.4) 0(1.5) -1.0(2.8) 0.73 0.76
8 weeks treatment 1.2(1.6) 2.2(2.1) -0.2(2.7) 0.48 0.48
Maximal Capillary Density (capillaries per field)
4 weeks treatment 1.5(1.7) 0.4(2.0) 3.0(3.0) 0.48 0.38
8 weeks treatment 1.8(1.3) 0.6(1.6) 3.5(2.3) 0.3 0.2
Pulse Wave Velocity (meters per second)
4 weeks treatment -0.1(0.3) -0.3(0.5) 0.04(0.4) 0.8 0.67
8 weeks treatment 0.1(0.4) 0.5(0.5) -0.5(0.7) 0.25 0.79
Central Systolic BP (mmHg)
4 weeks treatment -18.4(4.8) -18.5(7.3) -18.2(5.3) 0.98 0.002
8 weeks treatment -22.6(4.0) -24.9(6.0) -18.8(4.2) 0.5 <0.0001
Augmentation Index (%)
4 weeks treatment -7.6(2.5 -4.3(3.2) -13.0(2.7) 0.09 0.01
8 weeks treatment -9.2(2.0) -8.4(3.1) -10.5(1.7) 0.64 0.001
Table 3: Changes in variables from end of placebo run-in period to 4 and 8 weeks visit in randomized subjects.
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significantly reduced Aortic Augmentation Index but had no signifi-
cant effect on pulse wave velocity.
 Preclinical studies have suggested that treatment with antihyper-
tensive medications may reverse or even prevent microvascular rar-
efaction, although inconsistent results were obtained with different 
classes of drugs [17]. One study that compared the effects of different 
antihypertensive treatments on capillary density in Spontaneously 
Hypertensive Rats (SHR) led to the conclusion that despite their sim-
ilar effectiveness in decreasing BP, functional rarefaction was reversed 
by losartan, nifedipine and enalapril, while structural rarefaction was 
normalized only by losartan and enalapril while atenolol had no no-
ticeable effect [18]. It was therefore suggested that dihydropyridine 
CCB and rennin-angiotensin system blockers were effective in this 
regard, while data on diuretics and beta-blockers were inconclusive. 
These selective desirable effects on the microcirculation have been im-
plicated in explaining the beneficial effects of these drugs in reducing 
micro albuminuria and preserving renal function.
 Very little, however, is known about the effects of treatment of 
human essential hypertension on capillary rarefaction which may be 
related to end-organ damage, as suggested by the association between 
hypertensive myocardial disease and reduced myocardial capillary 
density [19]. Few observational and open label studies have shown 
inconsistent or even contradictory results about the reversal of micro-
vascular rarefaction with antihypertensive treatments [10,13,20,21]. It 
was postulated that treatment of hypertension and a reduction in BP 
represents a necessary but not a sufficient circumstance for inducing a 
regression in microvascular abnormalities, because drugs with similar 
hemodynamic profile may have dissimilar effects on small artery mor-
phology [22]. In a previous open-label pilot study in individuals with 
treatment-naive mild-to-moderate essential hypertension, we found 
that 6-weeks treatment with the ARB irbesartan resulted in significant 
lowering of both systolic and diastolic BP and significant increase in 
maximal capillary density (with venous congestion) [23]. In anoth-
er observational study we reported that capillary density was 25-30% 
higher in treated compared with untreated hypertensive patients but 
was significantly lower than in age-matched normotensive controls 
[11].
 Debbabi and colleagues, in an observational study, evaluated skin 
capillary density in hypertensive patients who were treated with dif-
ferent antihypertensive drugs and who had their BP well controlled 
below 140/90mmHg for at least 12 months. They found that basal 
(functional) and maximal (structural) skin capillary densities in treat-
ed hypertensive patients were significantly higher when compared to 
never-treated hypertensive patients or to normotensive subjects. 20 
The finding of a higher capillary density in treated hypertensive pa-
tients is very curious and rather difficult to construe [21]. In another 
open-label cross-sectional study the same group reported that only 
hypertensive patients who were treated and adequately controlled 
with perindopril/indapamide combination for more than 6 months 
had significantly higher maximal capillary density than both patients 
treated and controlled by other drugs, and normotensive individu-
als [13]. They suggested that the normalization of the skin capillary 
density could be, at least partially, BP independent as equivalent BP 
control is not synonymous with equivalent microvascular benefits and 
suggest different long-term results for end-organ damage. Of interest 
in their study is that most of the patients in the controlled-other group 
(48%) were treated with an ARB [13].
 Several other studies have shown similar negative effects of ARBs 
on capillary rarefaction. Kaiser and colleagues in an open-label ran-
domized design studied skin capillary density in 44 subjects with mild 
to moderate essential hypertension before and after six months treat-
ment with either a beta-blocker (metoprolol) or an ARB (olmesartan) 
[24]. Interestingly, they found that only treatment with metoprolol 
resulted in a significant reversal of rarefaction and an increase in cap-
illary density whilst treatment with olmesartan had no significant ef-
fect on capillary density. Treatment with valsartan showed conflicting 
results as one study showing significant increase in capillary density 
after only 4 weeks while another study showed no significant effect on 
capillary density [25,26]. These results are interesting in that they con-
tradict what has been suggested that drugs that block the rennin-an-
giotensin system e.g. ACEi and ARBs may be more efficacious than 
other drugs such as beta-blockers in reversing the microcirculatory 
abnormalities in hypertension [27].
 On the other hand, several other studies have shown no effect of 
hypertension treatment on capillary rarefaction. Penna et al., evaluat-
ed functional and structural capillary density in treated and well-con-
trolled patients with essential hypertension [12]. They found that 
treated hypertensive patients had lower mean functional capillary 
density at baseline, during post-occlusive reactive hyperemia and 
during venous congestion suggesting that treatment and control of 
BP, regardless of the type of therapy used, does not necessarily results 
in reversing capillary rarefaction. De Ciuceis and colleagues, in an 
open-label design, studied the effects of treatment of hypertension on 
structural alterations of retinal arterioles, skin capillary density, arteri-
al dispensability and oxidative stress with a CCB alone and the combi-
nation of a CCB with either an ACE inhibitor or a diuretic in patients 
with mild to moderate essential hypertension [10]. All their patients 
were treated with lercanidipine for 4 weeks and then either enalapril 
(n=10) or hydrochlorothiazide (n=10) was added for 6 months. They 
found no change in basal capillary density at any point in the study. 
After 4 weeks of treatment with lercanidipine alone, maximal capillary 
density was slightly but not significantly increased. After 6 months 
of treatment with the combination of lercanidipine and enalapril, the 
increase in maximal capillary density was statistically significant. The 
change in maximal capillary density with the combination of lercan-
idipine and hydrochlorothiazide was not statistically significant. Simi-
lar to our study, the authors found no change in PWV between groups 
or between any time points despite the fact that central SBP was sig-
nificantly reduced. More recently, the same group, in another ran-
domized open-label design, studied the effects of one-year treatment 
of hypertension with either ramipril or aliskiren and found no signifi-
cant effects on capillary rarefaction [28]. The results from our present 
study and the aforementioned studies suggest that the reduction and 
normalization of BP values may not be sufficient for obtaining a re-
gression of microvascular rarefaction in essential hypertension even 
after one year [29]. These findings also suggest that the improvement 
of capillary rarefaction and other microcirculatory abnormalities with 
selective ARBs or ACEi drugs may not represent a class effect but rath-
er drug-specific additional properties of these particular drugs on the 
microcirculation [13]. Our finding of no significant change in PWV in 
treated hypertensive patients is not novel, as other groups have found 
similar results [10,30-32].
 We acknowledge that our study has several limitations. Our in-
ability to find a significant effect of both candesartan and amlodipine 
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treatment on capillary rarefaction can be feasibly explained by the 
small number of subjects who completed the study (type 2 error) or 
the shorter duration of active treatment with these 2 drugs. Addi-
tionally we could not rule out any persisting effects of previous an-
tihypertensive medications our subjects received before enrolling in 
this study. It is also conceivable that amlodipine and candesartan may 
genuinely lack substantial microvascular effects as other studies have 
shown that treatment with amlodipine did not improve coronary flow 
reserve in hypertensive patients [33,34]. Similarly in the spontaneous-
ly hypertensive rat amlodipine and candesartan did not show any sig-
nificant reverse arteriolar remodeling compared to placebo [35].
 In conclusion, this study has shown that 4 weeks and 8 weeks treat-
ment with candesartan or amlodipine resulted in significant reduc-
tions of both systolic and diastolic brachial BP and central systolic BP 
but had no significant effect on basal (functional) or maximal (struc-
tural) capillary densities. These results indicate that normalization of 
BP with amlodipine or candesartan treatment does not necessarily re-
sults in reversal of capillary rarefaction in essential hypertension. The 
study also showed that both candesartan and amlodipine significantly 
reduced Aortic Augmentation Index but had no significant effect on 
pulse wave velocity.
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